Related references
Note: Only part of the references are listed.Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia
Anna Vardi et al.
CLINICAL CANCER RESEARCH (2016)
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
Carsten U. Niemann et al.
CLINICAL CANCER RESEARCH (2016)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib
Clare Sun et al.
BLOOD (2015)
B cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T cell clonality in chronic lymphocytic leukemia
N. Zaborsky et al.
HAEMATOLOGICA (2015)
Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias
Deepesh P. Lad et al.
LEUKEMIA & LYMPHOMA (2015)
B cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T cell clonality in chronic lymphocytic leukemia
N. Zaborsky et al.
HAEMATOLOGICA (2015)
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
Fabio Da Roit et al.
HAEMATOLOGICA (2015)
Chronic Lymphocytic Leukemia Cells Express CD38 in Response to Th1 Cell-Derived IFN-γ by a T-bet-Dependent Mechanism
Simone Burgler et al.
JOURNAL OF IMMUNOLOGY (2015)
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
Holbrook E. Kohrt et al.
BLOOD (2014)
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
Mohini Rajasagi et al.
BLOOD (2014)
T cell repertoire following autologous stem cell transplantation for multiple sclerosis
Paolo A. Muraro et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial
Susan O'Brien et al.
LANCET ONCOLOGY (2014)
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
Jan A. Burger et al.
LANCET ONCOLOGY (2014)
Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study
S. E. M. Herman et al.
LEUKEMIA (2014)
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling
Jan A. Burger et al.
BLOOD (2013)
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
John C. Riches et al.
BLOOD (2013)
IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells
Maria Fernanda Pascutti et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia Potential Clinical Implications
John C. Riches et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells
Ute E. Burkhardt et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
Jan A. Burger et al.
LEUKEMIA & LYMPHOMA (2013)
Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation
Jeroen W. J. van Heijst et al.
NATURE MEDICINE (2013)
Using synthetic templates to design an unbiased multiplex PCR assay
Christopher S. Carlson et al.
NATURE COMMUNICATIONS (2013)
Chronic Lymphocytic Leukemia Cells Are Activated and Proliferate in Response to Specific T Helper Cells
Audun Os et al.
CELL REPORTS (2013)
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
Alan G. Ramsay et al.
BLOOD (2012)
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
Davide Bagnara et al.
BLOOD (2011)
Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL
Petros Christopoulos et al.
BLOOD (2011)
Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia
Xiao-Jie Yan et al.
BLOOD (2011)
An αβ T Cell Receptor Structure at 2.5 Å and Its Orientation in the TCR-MHC Complex
K. Christopher Garcia et al.
JOURNAL OF IMMUNOLOGY (2010)
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
Harlan S. Robins et al.
BLOOD (2009)
CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment
Piers E. M. Patten et al.
BLOOD (2008)
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
BT Messmer et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Mechanisms of disease: Chronic lymphocytic leukemia
N Chiorazzi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia
MR Rezvany et al.
BLOOD (2003)
Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies
A Trojan et al.
NATURE MEDICINE (2000)
Share Paper
